You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

XELODA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Xeloda patents expire, and what generic alternatives are available?

Xeloda is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in XELODA is capecitabine. There are twenty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the capecitabine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xeloda

A generic version of XELODA was approved as capecitabine by TEVA PHARMS USA on September 16th, 2013.

  Try a Trial

Drug patent expirations by year for XELODA
Drug Prices for XELODA

See drug prices for XELODA

Recent Clinical Trials for XELODA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Columbia UniversityN/A
VarianN/A
Alliance Foundation Trials, LLC.Phase 3

See all XELODA clinical trials

Pharmacology for XELODA
Paragraph IV (Patent) Challenges for XELODA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
XELODA Tablets capecitabine 150 mg and 500 mg 020896 1 2008-11-10

US Patents and Regulatory Information for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cheplapharm XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Cheplapharm XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XELODA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cheplapharm XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 ⤷  Try a Trial ⤷  Try a Trial
Cheplapharm XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 ⤷  Try a Trial ⤷  Try a Trial
Cheplapharm XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ⤷  Try a Trial ⤷  Try a Trial
Cheplapharm XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for XELODA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
medac Gesellschaft für klinische Spezialpräparate mbH Capecitabine Medac capecitabine EMEA/H/C/002568
Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Authorised yes no no 2012-11-19
Accord Healthcare S.L.U. Capecitabine Accord capecitabine EMEA/H/C/002386
Capecitabine Accord is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Accord is indicated for the treatment of metastatic colorectal cancer.Capecitabine Accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Authorised yes no no 2012-04-20
Teva Pharma B.V. Capecitabine Teva capecitabine EMEA/H/C/002362
Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer.Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer.Capecitabine Teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Authorised yes no no 2012-04-20
CHEPLAPHARM Arzneimittel GmbH Xeloda capecitabine EMEA/H/C/000316
Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.Xeloda is indicated for the treatment of metastatic colorectal cancer.Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Authorised no no no 2001-02-02
Krka, d.d., Novo mesto Ecansya (previously Capecitabine Krka) capecitabine EMEA/H/C/002605
Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Authorised yes no no 2012-04-20
Sun Pharmaceutical Industries Europe B.V. Capecitabine SUN capecitabine EMEA/H/C/002050
Capecitabine is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine is indicated for the treatment of metastatic colorectal cancer.Capecitabine is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Withdrawn yes no no 2013-06-21
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for XELODA

See the table below for patents covering XELODA around the world.

Country Patent Number Title Estimated Expiration
Norway 300066 ⤷  Try a Trial
Iceland 1895 ⤷  Try a Trial
Hungary 211965 ⤷  Try a Trial
Hungary 199866 PROCESS FOR PRODUCTION OF DERIVATIVES OF FLUOR-CITIDIN AND MEDICAL COMPOSITIONS CONTAINING THEM ⤷  Try a Trial
Greece 3020286 ⤷  Try a Trial
U.S.S.R. 1736342 CПOCOБ ПOЛУЧEHИЯ ПPOИЗBOДHЫX 5 -ДEЗOKCИ-5-ФTOPЦИTИДИHA (METHOD OF 5'-DEOXY-5-FLUOROCYTIDINE SYNTHESIS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XELODA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0316704 2001C/021 Belgium ⤷  Try a Trial PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
0316704 C300045 Netherlands ⤷  Try a Trial PRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610
0316704 14/2001 Austria ⤷  Try a Trial PRODUCT NAME: CAPECITABIN; NAT. REGISTRATION NO/DATE: - 20010202; FIRST REGISTRATION: EU EU/1/00/163/001, EU/1/00/163/002 20010202
0316704 SPC/GB01/015 United Kingdom ⤷  Try a Trial PRODUCT NAME: CAPECITABINE AND HYDRATES AND SOLVATES THEREOF; REGISTERED: CH 54657 19980610; UK EU/1/00/163/001-002 20010202
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.